Andersen, Johanna B., Sharmin, Sifat, Lefort, Mathilde, Koch-Henriksen, Nils, Sellebjerg, Finn, Sørensen, Per Soelberg, Hilt Christensen, Claudia C., Rasmussen, Peter V., Jensen, Michael B., Frederiksen, Jette L., Bramow, Stephan, Mathiesen, Henrik K., Schreiber, Karen I., Horakova, Dana, Havrdova, Eva K., Alroughani, Read, Izquierdo, Guillermo, Eichau, Sara, Ozakbas, Serkan, Patti, Francesco, Onofrj, M, Lugaresi, A, Terzi, M, Grammond, P, Grand Maison, F, Yamout, B, Prat, A, Girard, M, Duquette, P, Boz, C, Trojano, M, McCombe, P, Slee, M, Lechner-Scott, Jenette, Turkoglu, R, Sola, P, Ferraro, D, Granella, F, Shaygannejad, V, Prevost, J, Skibina, O, Solaro, C, Karabudak, R, Wijmeersch, BV, Csepany, T, Spitaleri, D, Vucic, S, Casey, R, Debouverie, M, Edan, G, Ciron, J, Ruet, A, Sèze, JD, Maillart, E, Zephir, H, Labauge, P, Defer, G, Lebrun, C, Moreau, T, Berger, E, Clavelou, P, Pelletier, J, Stankoff, B, Gout, O, Thouvenot, E, Heinzlef, O, Al-Khedr, A, Bourre, B, Casez, O, Cabre, P, Montcuquet, A, Wahab, A, Camdessanché, JP, Marousset, A, Patry, I, Hankiewicz, K, Pottier, C, Maubeuge, N, Labeyrie, C, Nifle, C, Leray, E, Laplaud, DA, Butzkueven, H, Kalincik, T, Vukusic, S, Magyari, M. Elsevier; 2021. The effectiveness of natalizumab vs fingolimod - A comparison of international registry studies.

Kalincik, Tomas, Kubala Havrdova, Eva, Ozakbas, Serkan, Kappos, Ludwig, Kuhle, Jens, Terzi, Murat, Lechner-Scott, Jeanette, Boz, Cavit, Grand'maison, Francois, Prevost, Julie, Sola, Patrizia, Ferraro, Diana, Horakova, Dana, Granella, Franco, Trojano, M, Bergamaschi, R, Pucci, E, Turkoglu, R, McCombe, PA, Pesch, VV, Van Wijmeersch, B, Solaro, C, Ramo-Tello, C, Izquierdo, Guillermo, Slee, M, Alroughani, R, Yamout, B, Shaygannejad, V, Spitaleri, D, Sánchez-Menoyo, JL, Ampapa, R, Hodgkinson, S, Karabudak, R, Butler, E, Prat, Alexandre, Vucic, S, Jokubaitis, V, Spelman, T, Butzkueven, H, Girard, Marc, Duquette, Pierre, Grammond, Pierre, Onofrj, Marco, Lugaresi, Alessandra. B M J Group; 2019. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.

Nguyen, Ai-Lan, Havrdova, Eva Kubala, Horakova, Dana, Izquierdo, Guillermo, Kalincik, Tomas, van der Walt, Anneke, Terzi, Murat, Alroughani, Raed, Duquette, Pierre, Girard, Marc, Prat, Alexandre, Boz, Cavit, Sola, Patrizia, Ferraro, Dianna, Lugaresi, Alessandra, Lechner-Scott, Jeannette, Barnett, Michael, Grand'Maison, Francois, Grammond, Pierre, Ramo-Tello, Cristina, Turkoglu, R, McCombe, P, Pucci, E, Trojano, M, Granella, F, Spitaleri, D, Van Pesch, V, Soysal, A, Oreja-Guevara, C, Verheul, F, Vucic, S, Hodgkinson, S, Slee, M, Ampapa, R, Prevost, J, Menoyo, JLS, Skibina, O, Solaro, C, Olascoaga, J, Shaw, C, Madsen, KG, Naidoo, K, Hyde, R, Butzkueven, H, Jokubaitis, V. Elsevier; 2019. Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: a contemporary cohort study.